unc eshelman school of pharmacy highlights

8/6/2019 UNC Eshelman School of Pharmacy Highlights

1/17


2/17

Fast Facts

No 2 Ranked PharmD program (most recent rankingin US News & World Report)

Ranked #2 in NIH Funding, 2010 105 Faculty , 600 PharmD students, 110 Graduate

students

Over 200,000 sq ft of research/teaching space (3buildings) equipped with state-of-the art VTC and

distance education technology


3/17

PharmD PhD MS

Medicinal

Chemistry

&

Natural

Products

Molecular

Pharmaceutics

Pharmacotherapy

& Exp.

Therapeutics

Pharmaceutical

Outcomes

& Policy

Health System

Pharmacy

Academic Programs


4/17

Center for Integrative

Chemical Biology and

Drug Discovery

Center for Nanotechnology

in Drug Delivery

Institute for

Pharmacogenomics and

Individualized Therapy

Disease Targets

Leads

Pharmaceutical

Scientists

Novel Therapies

Novel Technologies

Formulation and

Drug DeliveryDisposition, Safety &

Efficacy in Clinic

Medicinal Chemistry

and Natural ProductsSynthetic Chemistry

Chemical Biology

Bio- and Chem-informatics

Structural Biology

Target Discovery & Validation

Molecular

PharmaceuticsDrug DeliveryFormulation

Gene Delivery

Nanotechnology

Material Science

Bioengineering

Pharmacotherapy

and ExperimentalTherapeuticsDrug Metabolism & transport

Pharmacogenomics

PK/PD Modeling & Simulation

Clinical Trial Design

Clinical Pharmacology


5/17

Discovery to Practice

Formulation and

Drug delivery

Molecular

Pharmaceutics

Disease targets,

Leads

Medicinal

Chemistry

&Natural

Products

Disposition,

Safety and

Efficacy in clinic

Pharmacotherapy

&

Experimental

Therapeutics

Effectiveness of

delivery,

Compliance

Pharmaceutical

Outcomes

&

Policy

Pharmacy

Practice &

Experiential

Education

Evaluation,

Development,

Education

Discovery Optimization Assessment Outcomes Practice


6/17

Center for Integrative Chemical Biology

& Drug Discovery (CICBDD)

Vision: The Center will be an innovative and sustainable scientific force in the creation of new small molecule therapeutics to improve

public health and to transform the drug discovery paradigm.

Center Capabilities

small

molecule

probes

drug

leads

target

validation

Target

Proposals

from

UNC Faculty

responsive

collaborations

Center

Initiated

Projects in

Chemical

Biology

prospective

science

CICBDD staff

& joint facultyAssay Development

Protein expression and purification

Cell-based or in vitroMultiple platforms and readouts

Compound ScreeningUp to 100K compounds possible

HTS

Medicinal ChemistrySAR projects11 internal chemists + 4 FTEs in

China and access to more as needed

Compound synthesis

Computational ChemistryDesign of screening sets

Virtual screening

Structure-based design

Director:

Stephen Frye

Features of CICBDD

Access to novel biological targets discovered by UNC facultyacross therapeutics areas

- targets validated with small molecules

Research focus on innovative targets in chromatin biology & epigentics NCI-designated Comprehensive Chemical Biology Center Leadership with industrial track record of discovery of FDA

approved drugs


7/17

The Center for Nanotechnology in Drug Delivery

(CNDD)

Th e f o cu s o f t h e CN DD is t o sa f e ly a n d e f fec t ive l y

t r a n s la t e n e w d r u g a n d im a g i n g d i s co v e r i e s in t o c lin i c a l

t r ia ls u s i n g n a n o t e ch n o lo g y w it h t h e g o a l t o im p r o v e h u m a n

h e a l t h .

Center for Nanotechnology in Drug Delivery (CNDD)

Five Critical

Areas/Disciplines:

1

Chemistry &

Biomaterials

Inst. for AdvancedMaterials

2

Formulation &

Drug Delivery

School ofPharmacy

3

Therapeutic &

Diagnostic Targets

Carolina Center of CancerNanobiotechnology Excellence

4

Nanotoxicology

RTP EPA, NIEHS

5

Phase I/II

Clinical Trials

UNC CTSA

CNDD Academic

Objectives:World leader in research,

training, and intellectual

property creation

CNDD Science

Objectives:First in human, proof of

safety and utility

CNDD Business

Objectives:Sustainable business

Model with ROI for

All stakeholders

CNDD StakeholdersFederal Agencies (NIH, NSF) State of NC

Private sector (VC, Industry) UNC students

UNC Academic/Research Units UNC-Chapel Hill

Director: Russ Mumper


8/17

The Hamner-UNC Institute for Drug Safety Sciences (IDSS)

in vitro in vivo postmarketingsurveillanceclinical

Computational Systems Modeling

Predictive Safety Assessment

A Platform for Integrated Drug Safety Research

Mission: Integrate clinical medicine with cutting-edge systems

biology and in silico modeling platforms to make drugs safer and

advance drug development.

Director: Paul Watkins


9/17

The Vital Partnership of Drug Discovery + Drug Delivery in Clinical Development

New Molecular Entities(problems)

Small moleculesUnstable

Insoluble

Efflux substrates

Poor permeability

Nucleic-acid basedUnstable

Poor permeability

Require intracellular

Accumulation

Peptides/proteinsUnstable

Poor permeability

Facilitate in-vitro screening

Stabilize NMEs

Increase cell accumulation

Range of dosage forms for various

routes of administration in pre-

clinical animal efficacy models

Advantageously affect ADME and

pharmacokinetics

Minimize toxicity, Safe (GRAS

materials)

Cost-effective

Scalable under GMP

CMC sections of IND

The Essence of Skills in the

Center for Nanotechnology in Drug Delivery

Drug Discovery Drug Delivery

+IIncreasedProbability

of Clinical

Success


10/17

Associate Directors:Oncology researchFederico Innocenti

Pre-clinical PGxTimothy Wiltshire

Policy and EthicsLynn Dressler

PGx Applied Technology

Karen Weck

Clinical PGxJames Evans

PGx Evidence-basedPracticesDan Jonas

IPIT is a collaboration of investigators, scientists,and clinicians across allied health schools within UNC with the

unifying goalof expediting the path from basic research

discoveries to clinical practice.

Preclinical Pharmacogenomics

Policy & Ethics

Applied Technology

Clinical PharmacogenomicsMedical Decision Making/Outcomes

Phenotype-driven therapy

Evidence-based medicine

Pharmaco-economics

School of Pharmacy

School of Medicine

School of Public Health

School of Nursing

Lineberger

Comprehensive

Cancer Center

Carolina Center

for Genome Sciences

IPIT

Research Areas

Director:

Howard McLeod


11/17

Translational Biomedical Research at UNC

Depts. Chemistry, Physics, Mathematics,

& Computer Science

Institute for Advanced Materials,Nanoscience and Technology (IAM)

Biomedical Research Imaging Center (BRIC)

Carolina Center of CancerNanotechnology Excellence (CCCNE)

North Carolina Center forNanoscale Materials (NCCNM)

Biomanufacturing Research Instituteand Technology Enterprise (BRITE)

Partial List of Key Partners:

Bryson Center for Human Genetics

North Carolina Translational and ClinicalSciences (TraCS) Institute (via NIH CTSA)

School of Medicine

Chemistry & Biology- High-throughout synthesis & screening- Bioassay development- Cheminformatics

Nanotechnology & Engineering- Materials discovery; Nanoengineering- Pharmaceutics; formulations- Biological stability; Nanotoxicology

Validated targetsConfirmed leads

Stable, lead formulations

In-VivoScreening

- Biological transport; delivery- Pharmacokinetics; ADME

Efficacious pre-clinical lead formulations

Genomics & Biology- Gene expression- Pharmacogenomics

Link molecular genetics to efficacy

CICBDD

IPIT

CenterforExp

loratoryCheminf

ormaticsResearch

Research TrianglePark

IndustryIndustry

Lineberger ComprehensiveCancer Center (LCCC)

UNC Institute for Nanomedicine

UNC Neuroscience Center

Carolina Cardiovascular Biology Center


12/17

Area Universities Pharmacy Spinoffs

Oriel Therapeutics

Research Triangle Park (RTP)

Pharma/Biotech companies

Relationships

Qualiber

UNC

Capture Pharmaceuticals

NeuroGate


13/17

Chemical Biology and Medicinal Chemistry

David

Lawrence, Ph.D.

Michael

Jarstfer, Ph.D.

Andrew

Lee, Ph.D.

Stephen

Frye, Ph.D.

Chemoinformatics,Bioinformatics, & Computation

Alexander

Tropsha, Ph.D.

Jian

Liu, Ph.D.

Glycobiology

BryanRoth, MD, Ph.D.

NIMH-PsychoactiveDrug Screening Program

Rihe

Liu, Ph.D.

Functional

Proteomics

Harold

Kohn, Ph.D.

Qisheng

Zhang, Ph.D.

K.H.

Lee, Ph.D.

Natural Products


14/17

Formulation & Drug Delivery

SamLai, Ph.D.

RussMumper, Ph.D.

MooCho, Ph.D.

RudyJuliano, Ph.D.

Michael

Jay, Ph.D.

LeafHuang, Ph.D.

Protein Dynamics NMR

Andrew

Lee, Ph.D.

Radiopharmaceutics

& Imaging

MichaelJay, Ph.D. RichardKowalski, Ph.D.

Pediatric Pharmacotherapy

Angela Kashuba,

PharmDDhiren

Thakker, Ph.D.

Michael

Cohen-Wolkoweitz


15/17

Metabolism/Transport/PK/PD/Pharmacometrics

Kim Brouwer

PharmD, Ph.D.

Dhiren

Thakker, Ph.D.

Mary

Paine Ph.D.

Philip

Smith, Ph.D.

Julie Dumond,

PharmD

Adam

Persky, Ph.D.

Cardiovascular Pharmacology

Craig Lee,

PharmD, Ph.D.

Herbert,

Patterson PharmD

Jo Ellen Rodgers,

PharmD

Mechanisms of Hepatotoxicity

Kim Brouwer

PharmD, Ph.D.Roy Hawke

PharmD, Ph.D.Paul Watkins,

M.D.


16/17

Infectious Diseases

Angela Kashuba,

PharmD

William Zamboni,

PhD, PharmD

Amanda

Corbett, PharmD

Julie Dumond,PharmD

Russ Mumper,PhD

Pharmacogenomics/Cancer Parmacotherapy

Howard McLeod,

PharmD

Tim

Wiltshire, Ph.D.

Lynn

Dressler, DrPH Federico Innocenti,MD, Ph.D.

William Zamboni,

PhD, PharmD

Christine

Walko, PharmD

SamLai, Ph.D.


17/17

Outcomes Research

Betsy

Sleath, Ph.D.

Mary

Roth McClurg, Ph.D.Susan Blalock,

MPH, Ph.D.Joel

Farley, Ph.D.

LynnDressler, DrPH

JayaRao, MD

Transplant Pharmacotherapy

RobertDupuis, PharmD

unc eshelman school of pharmacy highlights

Documents